Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Mallinckrodt
Covington
Farmers Insurance
Queensland Health
Express Scripts
Accenture
Harvard Business School
US Department of Justice
Citi

Generated: August 16, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,470,818 protect, and when does it expire?


Patent ► Subscribe protects ZELBORAF and is included in one NDA.

This patent has seventy-one patent family members in thirty-four countries.

Summary for Patent: ► Subscribe

Title:Compounds and methods for kinase modulation, and indications therefor
Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
Inventor(s): Ibrahim; Prabha N. (Mountain View, CA), Artis; Dean R. (Kensington, CA), Bremer; Ryan (Oakland, CA), Mamo; Shumeye (Oakland, CA), Zhang; Chao (Moraga, CA), Zhang; Jiazhong (Forster City, CA), Tsai; Jianming (Vallejo, CA), Hirth; Klaus-Peter (San Francisco, CA), Bollag; Gideon (Orinda, CA), Spevak; Wayne (Berkeley, CA), Cho; Hanna (Oakland, CA), Gillette; Samuel J. (Oakland, CA), Shi; Shenghua (San Diego, CA)
Assignee: Plexxikon Inc. (Berkeley, CA)
Application Number:12/906,980
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Hoffmann La Roche
ZELBORAF
vemurafenib
TABLET;ORAL202429-001Aug 17, 2011RXYesYes► Subscribe► Subscribe TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,846,941Compounds modulating c-kit and c-fms activity and uses therefor► Subscribe
8,143,271Compounds and methods for kinase modulation, and indications therefor► Subscribe
7,863,288Compounds and methods for kinase modulation, and indications therefor► Subscribe
8,415,469Compounds and methods for kinase modulation, and indications therefor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China102603581► Subscribe
Costa Rica9591► Subscribe
Costa Rica9677► Subscribe
Costa Rica20130216► Subscribe
Cyprus1111996► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Julphar
Fuji
Argus Health
Covington
Express Scripts
US Department of Justice
US Army
Moodys
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot